Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12190900 | 0.86 | RXFP1 (0.50) | MAPTPOLBKMT2AMEN1LMNA | |
| SCHEMBL12349302 | 0.82 | MAPT (0.46) | MAPTPOLBKMT2AKDM4EHTT | |
| SCHEMBL12349309 | 0.82 | MAPT (0.46) | MAPTPOLBKMT2AKDM4EHTT | |
| SCHEMBL18770800 | 0.82 | MGLL (0.55) | MGLLMAPTPOLBKMT2AHTT | |
| SCHEMBL29879853 | 0.82 | MGLL (0.55) | MGLLMAPTPOLBKMT2AHTT | |
| SCHEMBL20275927 | 0.81 | LMNA (0.58) | MGLLMAPTPOLBKMT2AHTT | |
| SCHEMBL12190854 | 0.80 | RXFP1 (0.46) | MGLLMAPTPOLBKMT2AMEN1 | |
| SCHEMBL2498455 | 0.80 | RXFP1 (0.53) | MGLLMAPTPOLBKMT2AMEN1 | |
| SCHEMBL14281162 | 0.78 | POLB (0.44) | MGLLMAPTPOLBNR1H3 | |
| SCHEMBL12349296 | 0.78 | RXFP1 (0.41) | MAPTPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817806-B1 | PHENOTHAZINES-S-OXIDES AND S,S-DIOXIDES AS hole and excitonblockers for OLEDs | BASF SE (DE) | 2014-07-30 | — | — | EP | disclosed |
| US-8029919-B2 | Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs | BASF AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8029919-B2 | Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs | BASF AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8029919-B2 | Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs | BASF AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | BASF AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | BASF AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | BASF AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20080018238-A1 | Use Of Phenothiazine-S-Oxides And Phenothiazine -S,S-Dioxides In The Form Of Matrix Materials For Organic Light-Emitting Diodes | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
| US-20080018238-A1 | Use Of Phenothiazine-S-Oxides And Phenothiazine -S,S-Dioxides In The Form Of Matrix Materials For Organic Light-Emitting Diodes | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | PPOX, SMOX, SORD | MGLL 2146/4885MAPT 218/4885POLB 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.